- Home
- PRTA
as 11-07-2025 3:57pm EST
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 472.1M | IPO Year: | N/A |
| Target Price: | $17.71 | AVG Volume (30 days): | 567.7K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $18.64 | Next Earning Date: | 11-06-2025 |
| Revenue: | $11,786,000 | Revenue Growth: | -91.16% |
| Revenue Growth (this year): | -84.44% | Revenue Growth (next year): | 672.02% |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Why The Narrative Around Prothena Is Shifting Amid Analyst Optimism and New Developments
Zacks
2 days ago
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
2 days ago
Prothena: Q3 Earnings Snapshot
Business Wire
2 days ago
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
Business Wire
9 days ago
Prothena to Report Third Quarter 2025 Financial Results on November 6
Simply Wall St.
23 days ago
One Prothena Insider Raised Their Stake In The Previous Year
Business Wire
a month ago
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
BioPharma Dive
5 months ago
Prothena to lay off majority of staff; Zealand shares obesity drug data
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.